Anti-hepatitis a virus antibodies

Details Anti-hepatitis a virus antibodies Anti-hepatitis a virus antibodies

2007-04-23

2009-12-22

Peng, Bo (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S139100, C530S388100, C530S388200, C530S388300, C435S320100, C435S069100, C435S007100

Reexamination Certificate

active

07635476

ABSTRACT:
Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.

REFERENCES:
patent: 4444487 (1984-04-01), Miller et al.
patent: 4614793 (1986-09-01), Hughes et al.
patent: 4745055 (1988-05-01), Schenk et al.
patent: 4777245 (1988-10-01), Foung et al.
patent: 6106835 (2000-08-01), Chang
patent: 120694 (1984-10-01), None
patent: 125023 (1984-11-01), None
patent: 256654 (1988-02-01), None
patent: WO 87/01131 (1987-02-01), None
patent: WO 88/03565 (1988-05-01), None
patent: WO 01/40270 (2001-06-01), None
Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J. SDR grafting—a new approach to antibody humanization. Methods. May 2005;36(1):25-34. Review.
Tamura M, et al. “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.” J Immunol. Feb. 1, 2000;164(3):1432-41.
Gane et al., “Clinical recurrence of hepatitis A following liver transplantation for acute liver failure,”J. Medical Virol. 45:35-39, 1995.
Schofield et al., “Identification by Phage Display and Characterization of Two Neutralizing Chimpanzee Monoclonal Antibodies to the Hepatitis E Virus Capsid Protein,”J. Virol. 74(12):5548-5555, 2000.
Schofield et al., “Four Chimpanzee Monoclonal Antibodies Isolated by Phage Display Neutralize Hepatitis A Virus,”Virology292:127-136, 2002.
Van Meel et al., “Human and Chimpanzee Monoclonal Antibodies,”J. Immunol. Methods80:267-276, 1985.
Zesheng et al., “Selection of Human Anti-HAV McAb from a Phage Antibody Library,”Chinese J. Biotech. 14(3):173-178, 1999.
Barbas, et al., “Assembly of Combinatorial Antibody Library on Phage Surfaces: the Gene III Site,”Proc. Natl. Acad. Sci U.S.A. 88:7978-7982, 1991.
Ciocca, “Clinical Course and Consequences of Hepatitis A Infection,”Vaccine18 Suppl. 1, S71-74, 2000.
Falkner et al., “Expression of Mouse Immunoglobulin Genes in Monkey Cells,”Nature298:286-288, 1982.
Lefilliatre et al., “Fulminant Hepatitis A in Patients with Chronic Liver Disease,”Can. J. Public Health91(3), 168-170, 2000.
Macgregor et al., “Monoclonal Antibodies Against Hepatitis A Virus,”J. Clin. Microbiol. 18(5): 1237-1243, 1983.
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,”J. Mol. Biol. 222:581-597, 1991.
Morrison, “Sequentially Derived Mutants of the Constant Region of the Heavy Chain of Murine Immunoglobulins,”J. Immunol. 123(2):793-800, 1979.
Morrison et al., “Transfer and Expression of Immunoglobulin Genes,”Ann Rev. Immunol. 2:239-256, 1984.
Nainan, Identification of Amino Acids Located in the Antibody Binding Sites of Human Hepatitis A Virus,Virology191(2): 984-987, 1992.
O'Grady, “Fulminant hepatitis in patients with chronic liver disease,”J. Viral Hepat. 7 Suppl. 1, 9-10, 2000.
Ping et al., “Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus,”Proc. Natl. Acad. Sci. U.S.A. 85(21): 8281-8285, 1988.
Ping et al., “Antigenic Structure of Human Hepatitis A Virus Defined by Analysis of Escape Mutants Selected against Murine Monoclonal Antibodies,”J. Virol. 66(4): 2208-2216, 1992.
Silberstein, et al., Neutralization of Hepatitis A Virus (HAV) by an Immunoadhesion Containing the Cysteine-Rich Region of HAV Cellular Receptor-1,J. Virol. 75(2): 717-725, 2001.
Stapleton et al., “Neutralization Escape Mutants Define a Dominant Immunogenic Neutralization Site on Hepatitis A Virus,”J. Virol. 61(2): 491-498, 1987.
Tsarev et al., “Simian hepatitis A virus (HAV) strain AGM-27: comparison of genome structure and growth in cell culture with other HAV strains,”J. Gen. Virol. 72(7): 1677-1683, 1991.
Uhlig et al., “Intertypic Cross-Neutralization of Polioviruses by Human Monoclonal Antibodies,”Virology163(1), 214-217, 1988.
Vento, “Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C,”J. Viral Hepat. 7 Suppl. 1, 7-8, 2000.
Watson et al., eds., Chapter 7 inRecombinant DNA, W.H. Freeman and Co., New York, p. 99-133, 1992.
Williamson et al., “Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries,”Proc. Natl. Acad. Sci. U.S.A. 90(9): 4141-4145, 1993.
Yang et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,J. Mol. Biol. 254(3): 392-403, 1995.
US-10-494-676-3.RPR: Alignments, 1 page, (Jul. 14, 2006).
The Office action from U.S. Appl. No. 10/494,676, (dated Jul. 14, 2009).

Affiliated with

Also associated with

Rating

Anti-hepatitis a virus antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-hepatitis a virus antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-hepatitis a virus antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4052490